On November 9, 2022, Shanghai Yingli Pharmaceutical Co., Ltd. (hereinafter referred to as "YL-Pharma") announced that the Class 1 anti-cancer new drug linperlisib has been approved for marketing by the China National Medical Products Administration (NMPA) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL), under the trade name Yin Tai Rui®.

To implement the innovation-driven development strategy, accelerate the construction of a science and technology innovation center with global influence, and promote the construction of enterprise technology centers in Jing'an District, the Jing'an District Commerce Committee organized the application and evaluation work for the 2022 Jing'an District Enterprise Technology Center.

On August 27, the Small Molecule Innovative Drugs Yangtze River Delta Primary and Secondary Market Corporate Leaders Closed-door Meeting, co-hosted by Pineclub and Genhouse, was successfully held in Suzhou. At the meeting, Junlin Wang, founder and chairman of UnionClin, delivered a keynote speech titled "Challenges and Solutions in Early Clinical Studies of Innovative Anti-Tumor Drugs".

2017 is called the "First Year of Innovative Drugs" by the pharmaceutical industry in China.

On August 6, the "Innovative Drug Clinical Study Summit Forum", part of the 2022 Shanghai International Biopharmaceutical Industry Week Series of Events, was opened.